Skip to main content
SpringerLink
Log in

Nail Psoriasis

Clinical Presentation and Best Practice Recommendations

  • Therapy In Practice
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Nail involvement in psoriasis is common and can have a significant impact on quality of life. Manifestations of nail dystrophy in psoriasis include pitting, onycholysis, subungual hyperkeratosis and splinter haemorrhages. Clear evidence regarding the range of treatment options for nail psoriasis is lacking. Topical therapies, including corticosteroids and vitamin D3 analogues, are simple to administer and readily available, but are not effective in treating all types of psoriatic nail dystrophy. Other topical agents have been tried, but may be less readily available. Intralesional corticosteroid injections can be helpful, but may be painful and time consuming. Psoralen plus ultraviolet A treatment has been shown to improve subungual hyperkeratosis, onycholysis, discolouration and nail crumbling, but not pitting. The possibility of future harm with other types of radiation treatment, including superficial radiotherapy and Grenz rays, limits their use. The use of systemic therapies, including the recent introduction of biological agents, is largely restricted to those with concomitant widespread cutaneous or joint involvement because of cost implications and potential toxicity. Further studies regarding the treatment of nail psoriasis are required in order to ascertain the best regimen of therapy for each patient.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Table I
Table II

Similar content being viewed by others

References

  1. de Berker DAR. Management of nail psoriasis. Clin Exp Dermatol 2000; 25: 357–62

    Article  PubMed  Google Scholar 

  2. de Jong EMGJ, Seegers BAMPA, Gulinck MK, et al. Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1728 patients. Dermatology 1996; 193: 300–3

    Article  PubMed  Google Scholar 

  3. Jiaravuthisan MM, Sasseville D, Vender RB, et al. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol 2007; 57: 1–27

    Article  PubMed  Google Scholar 

  4. Cassell S, Kavanaugh AF. Therapies for psoriatic nail disease: a systematic review. J Rheumatol 2006; 33: 1452–6

    PubMed  CAS  Google Scholar 

  5. deBerker DAR, Baran R, Dawber RPR. The nail in dermatological diseases. In: Baran R, Dawber RPR, de Berker DAR, et al., editors. Baran and Dawber’s diseases of the nails and their management. 3rd ed. Oxford: Blackwell Science, 2001: 172–93

    Chapter  Google Scholar 

  6. Rich P, Scher RK. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003; 49: 206–12

    Article  PubMed  Google Scholar 

  7. Tosti A, Piraccini BM, Cameli N, et al. Calcipotriol in nail psoriasis: a controlled double blind comparison with betamethasone dipropionate and salicylic acid. Br J Dermatol 1998; 139: 655–9

    Article  PubMed  CAS  Google Scholar 

  8. Rigopoulos D, Ioannides D, Prastitis N, et al. Nail psoriasis: a combined treatment using calcipotriol cream and clobetasol propionate cream [letter]. Acta Dermatol Venereol 2002; 82: 140

    Article  CAS  Google Scholar 

  9. Frederiksson T. Topically applied fluorouracil in the treatment of psoriatic nails. Arch Dermatol 1974; 110: 735

    Article  Google Scholar 

  10. de Jong EM. Dystrophic psoriatic fingernails treated with 1% fluorouracil in a nail penetration-enhancing vehicle: a double-blind study. Dermatology 1999; 199: 313–8

    Article  PubMed  Google Scholar 

  11. Yamamoto T, Katayama I, Nishioka K. Topical anthralin therapy for refractory nail psoriasis. J Dermatol 1998; 25: 231–3

    PubMed  CAS  Google Scholar 

  12. Scher RK, Stiller M, Zhu YI. Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double-blind, randomized, vehicle-controlled study. Cutis 2001; 68: 355–8

    PubMed  CAS  Google Scholar 

  13. Bianchi L, Soda R, Diluvio L, et al. Tazarotene 0.1% gel for psoriasis of the fingernails and toenails: an open, prospective study. Br J Dermatol 2003; 149: 1207–9

    Article  Google Scholar 

  14. Tosti A, Guerra L, Bardazzi F, et al. Topical ciclosporin in nail psoriasis [letter]. Dermatologica 1990; 180: 110–2

    Article  PubMed  CAS  Google Scholar 

  15. Cannavo SP, Guarneri F, Vaccaro M, et al. Treatment of psoriatic nails with topical cyclosporine: a prospective randomized placebo-controlled study. Dermatology 2003; 206: 153–6

    Article  PubMed  CAS  Google Scholar 

  16. Deffer TA, Goette DK. Distal phalangeal atrophy secondary to topical steroid therapy. Arch Dermatol 1987; 123: 571–2

    Article  PubMed  CAS  Google Scholar 

  17. Wolf R, Tur E, Brenner S. Corticosteroid-induced ‘disappearing digit’. Arch Dermatol 1990; 23: 755–6

    CAS  Google Scholar 

  18. Requena L, Zamora E, Martin L, et al. Acroatrophy secondary to longstanding applications of topical steroids. Arch Dermatol 1990; 126: 1013–4

    Article  PubMed  CAS  Google Scholar 

  19. Tzung TY, Chen CY, Yang CY, et al. Calcipotriol used as monotherapy or combination therapy with betamethasone dipropionate in the treatment of nail psoriasis. Acta Derm Venereol 2008; 88(3): 279–80

    PubMed  Google Scholar 

  20. Rigopoulos D, Gregoriou S, Katsambas A. Treatment of psoriatic nails with tazarotene cream 0.1% versus clobetasol propionate 0.05% cream: a double-blind study [letter]. Acta Derm Venereol 2007; 87: 167–9

    Article  PubMed  CAS  Google Scholar 

  21. Prins AM, Vos K, Franssen EJ. Instability of topical ciclosporin emulsion for nail psoriasis. Dermatology 2007; 215(4): 362–3

    Article  PubMed  CAS  Google Scholar 

  22. Kalb RE, Bagel J, Korman NJ, et al. Treatment of inter-triginous psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2009 Jan; 60(1): 120–4

    Article  PubMed  Google Scholar 

  23. de Berker DAR, Lawrence CM. A simplified protocol of steroid injection for psoriatic nail dystrophy. Br J Dermatol 1998; 138: 90–5

    Article  PubMed  Google Scholar 

  24. Gerstein W. Psoriasis and lichen planus of the nails: treatment with triamcinolone. Arch Dermatol 1962 Oct; 86: 419–21

    Article  PubMed  CAS  Google Scholar 

  25. Abell E, Samman PD. Intradermal triamcinolone acetonide for nail dystrophies. Br J Dermatol 1973; 89: 191–7

    Article  PubMed  CAS  Google Scholar 

  26. Bleeker JJ. Intralesional triamcinolone acetonide using the Port-o-jet and needle injections in localized dermatoses. Br J Dermatol 1974; 91: 479–84

    Article  Google Scholar 

  27. Peachey RDG, Pye RJ, Harman RRM. The treatment of psoriatic nail dystrophy with intradermal steroid injections. Br J Dermatol 1976; 95: 75–8

    Article  PubMed  CAS  Google Scholar 

  28. Marx JL, Scher RK. Response of psoriatic nails to oral photochemotherapy. Arch Dermatol 1980; 116: 1023–4

    Article  PubMed  CAS  Google Scholar 

  29. Handfield-Jones SE, Boyle J, Harman RRM. Local PUVA treatment for nail psoriasis. Br J Dermatol 1987; 116: 280–1

    Article  PubMed  CAS  Google Scholar 

  30. Finnerty EF. Successful treatment of psoriasis of the nails. Cutis 1979; 23: 43–4

    PubMed  CAS  Google Scholar 

  31. Yu RCH, King CM. A double-blind study of superficial radiotherapy in psoriatic nail dystrophy. Acta Dermatol Venereol 1992; 72: 124–36

    Google Scholar 

  32. Lindelof B. Psoriasis of the nails treated with Grenz rays: a double-blind bilateral trial. Acta Dermatol Venereol 1989; 69: 80–2

    CAS  Google Scholar 

  33. Kwang TY, Nee TS, Seng KTH. A therapeutic study of nail psoriasis using electron beams [letter]. Acta Dermatol Venereol 1995; 75: 90

    CAS  Google Scholar 

  34. Tosti A, Ricotti C, Romanelli P, et al. Evaluation of the efficacy of acitretin for nail psoriasis. Arch Dermatol 2009; 145(3): 269–71

    Article  PubMed  CAS  Google Scholar 

  35. Mahrle G, Schulze HJ, Farber L, et al. Low-dose short term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement. J Am Acad Dermatol 1995; 32: 78–88

    Article  PubMed  CAS  Google Scholar 

  36. Arnold WP, Gerritsen MJP, van de Kerkhof PCM. Response of nail psoriasis to cyclosporine. Br J Dermatol 1993; 129: 750–1

    Article  PubMed  CAS  Google Scholar 

  37. Syuto T, Abe M, Ishibuchi H, et al. Successful treatment of psoriatic nails with low-dose cyclosporine administration [letter]. Eur J Dermatol 2007; 17(3): 248–9

    PubMed  Google Scholar 

  38. Feliciani C, Zampetti A, Forleo P, et al. Nail psoriasis: combined therapy with systemic cyclosporine and topical calcipotriol. J Cutan Med Surg 2004; 8: 122–5

    Article  PubMed  Google Scholar 

  39. Vlachou C, Berth-Jones J. Nail psoriasis improvement in a patient treated with fumaric acid esters. J Dermatol Treat 2007; 18: 175–7

    Article  CAS  Google Scholar 

  40. Lawry M. Biological therapy and psoriasis. Dermatol Ther 2007 Jan–Feb; 20(1): 60–7

    Article  PubMed  Google Scholar 

  41. Rich P, Griffiths CE, Reich K, et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during one year. J Am Acad Dermatol 2008 Feb; 58(2): 224–31

    Article  PubMed  Google Scholar 

  42. Rigopoulos D, Gregoriou S, Stratigos A, et al. Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study. Br J Dermatol 2008 Aug; 159(2): 453–6

    Article  PubMed  CAS  Google Scholar 

  43. Hussain W, Coulson I, Owen C. Severe recalcitrant nail psoriasis responding dramatically to infliximab: report of two patients. Clin Exp Dermatol 2008 Jul; 33(4): 520–2

    Article  PubMed  CAS  Google Scholar 

  44. Barrera MV, Habicheyn S, Mendiola MV. Etanercept in the treatment and retreatment of psoriasis in daily practice. Eur J Dermatol 2008; 18(6); 683–7

    PubMed  CAS  Google Scholar 

  45. Efficacy and safety results from the randomized controlled comparative study of adalimumab versus placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158(3): 558–66

    Google Scholar 

  46. Ko JM, Gottileb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatol Treat 2008 Oct; 16: 1–8

    Google Scholar 

  47. Sfikakis PP, Iliopoulos A, Elezoglou A, et al. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum 2005 Aug; 52(8): 2513–8

    Article  PubMed  CAS  Google Scholar 

  48. Lamerson C, Stevens G, Sax K. Treatment of nail psoriasis with efalizumab: a preliminary study. Cutis 2008 Sep; 82(3): 217–20

    PubMed  Google Scholar 

  49. Korver JEM, Langewouters AMG, Van de Kerkhof PCM, et al. Therapeutic effects of a 12-week course of alefacept on nail psoriasis. J Eur Acad Dermatol Venereol 2006; 20: 1252–5

    Article  PubMed  CAS  Google Scholar 

  50. Noiles K, Vender R. Nail psoriasis and biologics. J Cutan Med Surg 2009; 13(1): 1–5

    PubMed  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Bristol Dermatology Centre, Bristol Royal Infirmary, Marlborough St, Bristol, BS2 8HW, UK

    Felicity Edwards & David de Berker

Authors
  1. Felicity Edwards
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David de Berker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Felicity Edwards.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Edwards, F., de Berker, D. Nail Psoriasis. Drugs 69, 2351–2361 (2009). https://doi.org/10.2165/11318180-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11318180-000000000-00000

Keywords

Search

Navigation